经尿道灌注溶瘤病毒 CG0070 治疗膀胱癌。
Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer.
机构信息
CG Oncology, Inc., Irvine, CA, USA.
Department of Pharmacy, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
出版信息
Methods Mol Biol. 2023;2684:303-317. doi: 10.1007/978-1-0716-3291-8_19.
CG0070 is a conditionally replicating oncolytic adenovirus that preferentially replicates within and kills Rb-defective cancer cells. It has been used successfully in an intravesical formulation to treat Bacillus Calmette-Guerin (BCG) unresponsive carcinoma in situ (CIS) containing non-muscle-invasive bladder cancer. As a self-replicating biologic, it shares many characteristics with intravesical BCG but has other unique features. Herein, we detail recommended standardized protocols for bladder infusion of CG0070 for the treatment of bladder cancer and provide many useful tips for trouble shooting.
CG0070 是一种条件复制的溶瘤腺病毒，它在 Rb 缺陷型癌细胞内优先复制并杀死这些细胞。它已成功地被应用于膀胱内制剂，以治疗包含非肌肉浸润性膀胱癌的卡介苗（BCG）无应答性原位癌（CIS）。作为一种自我复制的生物，它与膀胱内 BCG 有许多共同特征，但也有其他独特的特征。本文详细介绍了 CG0070 膀胱内灌注治疗膀胱癌的推荐标准化方案，并提供了许多解决问题的有用提示。
Zotero 插件